CRSP News and Press, CRISPR Therapeutics AG From 01/22/24

2024-01-22 13:52:27 ET Summary The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the approval, causing a drop in stock prices for Vertex and C...

2024-01-21 09:37:00 ET Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make...

2024-01-21 08:00:00 ET You've probably heard that bleeding-edge biotechs like Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) are working hard to develop gene therapies to cure intractable hereditary illnesses. That's entirely true. But for invest...

2024-01-20 06:50:00 ET Many stocks that have delivered big gains eventually succumb to the investing equivalent of gravity. However, not all of them do. Some keep the momentum going and going. Three Motley Fool contributors think that they've found high-flying stocks that can go much hi...

2024-01-20 05:00:00 ET Summary NZS Capital is an investment company focused on adaptable, innovative businesses that work toward maximizing non-zero-sum (NZS, or win-win) outcomes for their investors, customers, employees, society, and the global environment. The flagship strategy...

2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...

2024-01-18 02:34:26 ET Summary CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible through an in-vivo solution. The concerns surround...

2024-01-17 17:00:00 ET Many Canadian investors are likely already familiar with Warren Buffett. However, you may not be as familiar with Cathie Wood. Cathie Wood is also one of the most popular investment strategists in the United States. And it’s why we turn our attention to Cathie ...

2024-01-17 06:40:47 ET Summary Global portfolio managers prefer the Information Technology and Healthcare sectors for 2024, per a recent Goldman Sachs survey. ARK Innovation ETF is a tech-heavy active ETF that has been consolidating after a strong 2023, underperforming the S&P...

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-ba...